Login
$IPSC
$1.64 -$0.00 (0.18%) After hours

$IPSC 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

CNTY-813, an iPSC-derived islet replacement therapy for T1D, presented new nonclinical data at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) and remains on track for IND submission in 4Q 2026; initi...

02 Oct 2026 8-K: Regulation FD Disclosure; Other Events

CNTY - 813: Scalable Production of Allo - Evasion TM 5.0 - Engineered iPSC Islets for Off - the - Shelf Cell Therapies G. Grant Welstead, PhD SVP, Head of Research

09 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

PHILADELPHIA, September 9, 2026 - Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1...

12 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026

16 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

On June 15, 2026, Century Therapeutics, Inc. (the “Company”) entered into an Amended and Restated Employment Agreement (the “A&R Agreement”) with Chad Cowan, Ph.D., the Company’s Chief Scientific Officer. Pursuant to the A&R Agreement, D...

12 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Century Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that:

08 Jun 2026 8-K: Other Events

CNTY-813: Scalable Production of Allo-Evasion 5.0- Engineered iPSC Islets for Off-the-Shelf Cell Therapies Leonardo Velazco-Cruz, PhD

13 May 2026 8-K: Results of Operations and Financial Condition

CNTY-813, Century’s type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027

26 Mar 2026 8-K: Other Events

Re: Securities Registered under Registration Statement on Form S-3

12 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial clinical data in 2H ...

23 Jan 2026 8-K: Submission of Matters to a Vote of Security Holders; Other Events

On January 22, 2026, Century Therapeutics, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). As of November 25, 2025, the record date for the Special Meeting, there were 87,405,311 outstanding shares of...

12 Jan 2026 8-K: Regulation FD Disclosure

2 Forward - looking statements This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contai...

08 Jan 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of January 7, 2026 by and among Century Therapeutics, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached here...

29 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

12 Dec 2025 8-K: Regulation FD Disclosure

Advancing Pipeline of Transformative Cell Therapies Corporate Deck – December 2025

09 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

PHILADELPHIA, Dec. 9, 2025 -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced the ap...

13 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more

Announced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026

29 Aug 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

14 Aug 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025

07 Jul 2025 8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation

On July 1, 2025, the Board of Directors (the “Board”) of Century Therapeutics, Inc. (the “Company”) approved a reduction in force as part of a broader effort to right size the organization to focus on programs with the highest potential ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support